Drugs / Progerinin
Progerinin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04512963 | Aug 2020 → Jul 2021 | Hutchinson-Gilford progeria syndrome, Werner syndrome | PRG Science & Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05847179 | Oct 2026 → Dec 2027 expected | Werner syndrome | PRG Science & Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06775041 | Jan 2025 → Mar 2026 | Hutchinson-Gilford progeria syndrome | PRG Science & Technology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Progerinin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04512963 ↗ |
| Known as | Progerinina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1631723 ↗ |
| Known as | Progerinine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1631723 ↗ |
| Known as | SLC-D011 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1631723 ↗ |
| Action | Inhibit | “Progerinin binds specifically to progerin reduces its expression” NCT04512963 ↗ |
| Modality | Small molecule | — CHEMBL1631723 ↗ |
| Route | Oral | “100 mg/g nano-suspension for oral use” NCT04512963 ↗ |